In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. e12608-e12608
Abstract:
e12608 Background: HER2-positive breast cancer is the more suitable subtype to perform a neoadjuvant therapy with chemotherapy and antiHER2 therapy because a high pathologic response and significance survival. However, despite this high percentage of pathological responses, there are still recurrences that can affect survival. Methods: We analyze a cohort of 287 HER-2 positive breast cancer treated with neoadjuvant chemotherapy and antiHER2 therapy according to current guidelines, to find the factors that could induce a recurrence. Results: Median age was of 56 (28-89), median tumor size of 37 mm (12-140), 145 (50%) had nodal involvement, estrogen receptor positive in 152 patients (53%) and median ki67 expression of 41% (3-95). HER2 expression by inmunohistochemistry was 2+ in 83 patients (29%) and 3+ in 204 (71%). A total of 50% complete pathological response (pCR) rate was detected and 54 (18,8%) relapsed. 17 patients with pCR (12%) and 37 patients without pCR (25%) had a recurrence (OR 4,31, p: 0,003). The factors that most influenced the relapse in the group of patients with pCR were: the initial size (greater than 5 cm) 30% of relapses, the initial axillary involvement (19%) and the cases with HER2 +3 expression and estrogen receptor negative (17%). In the group without pCR, the relapse was more frequent in patients with HER2 +2 expression and estrogen receptor negative (40%), HER2 +3 expression and estrogen receptor negative (43%), initial tumor size greater than 5 cm (38%) and axillary involvement (38%). Conclusions: Although pCR continues to be the most important factor to avoid relapse, there are other factors that must be considered as determinants of relapse despite achieving a pCR. Initial size greater than 5 cm is a poor prognostic factor despite reaching a pCR with up to 30% relapses, so other adjuvant interventions should be considered after initial neoadjuvant treatment.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2022.40.16_suppl.e12608
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2022
detail.hit.zdb_id:
2005181-5
Permalink